These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623 [TBL] [Abstract][Full Text] [Related]
5. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
8. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
9. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Mohty B; El-Cheikh J; Yakoub-Agha I; Avet-Loiseau H; Moreau P; Mohty M Leukemia; 2012 Jan; 26(1):73-85. PubMed ID: 22024721 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
16. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Jagannath S; Dimopoulos MA; Lonial S Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288 [TBL] [Abstract][Full Text] [Related]
17. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. van de Donk NW; Lokhorst HM Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099 [TBL] [Abstract][Full Text] [Related]
18. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]